Olita (olmutinib) / Hanmi  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Olita (olmutinib) / Hanmi
NCT02444819: Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy

Completed
2
33
RoW
HM61713, Olmutinib
Hanmi Pharmaceutical Company Limited
Non Small Cell Lung Cancer
08/17
08/17
NCT03228277: Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA

Completed
2
25
RoW
Olmutinib, Olita®
Konkuk University Medical Center, Hanmi Pharmaceutical Company Limited
Non Small Cell Lung Cancer
07/18
07/19
NCT02485652 / 2015-001435-21: Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung

Terminated
2
162
Europe, Canada, US, RoW
HM61713, Olmutinib
Hanmi Pharmaceutical Company Limited
Non Small Cell Lung Cancer
12/20
12/20
NCT01588145: Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients

Checkmark ELCC 2016
Apr 2016 - Apr 2016: ELCC 2016
Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
1/2
273
RoW
HM61713, Olmutinib
Hanmi Pharmaceutical Company Limited
Non Small Cell Lung Cancer
08/17
08/17

Download Options